Lithium chloride attenuates the abnormal osteogenic/adipogenic differentiation of bone marrow-derived mesenchymal stem cells obtained from rats with steroid-related osteonecrosis by activating the β-catenin pathway

ZEFENG YU*, LIHONG FAN†, JIA LI, ZHAOGANG GE, XIAOQIAN DANG and KUNZHENG WANG

Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China

Received July 6, 2015; Accepted August 27, 2015

DOI: 10.3892/ijmm.2015.2340

Abstract. Steroid-related osteonecrosis of the femoral head (ONFH) may be a disease that results from the abnormal osteogenic/adipogenic differentiation of bone marrow-derived mesenchymal stem cells (BMMSCs). In the present study, we examined the possible use of lithium in an aim to reverse the abnormal osteogenic/adipogenic differentiation of BMMSCs isolated from rats with steroid-related ONFH (termed ONFH-BMMSCs). BMMSCs obtained from steroid-related ONFH rat femurs were cultured with or without lithium chloride (LiCl). BMMSCs obtained from normal rat femurs were cultured as controls. LiCl significantly increased the expression of osteocalcin and Runx2 in the ONFH-BMMSCs during osteogenic induction. The mineralization of ONFH-BMMSCs following osteogenic induction was also enhanced. Furthermore, LiCl exerted anti-adipogenic effects on the ONFH-BMMSCs by inhibiting the expression of peroxisome proliferator-activated receptor γ (PPARγ) and fatty acid binding protein 4 (Fabp4) during adipogenic induction, and decreasing lipid droplet formation at the end of adipogenic induction. These effects of LiCl on the ONFH-BMMSCs were associated with an increased expression of β-catenin and a decreased expression of phosphorylated GSK-3β at Tyr-216, and these effects were abolished by treatment with quercetin, an antagonist of the β-catenin pathway. The normal osteogenic/adipogenic activity of BMMSCs may be impaired in steroid-related ONFH. However, as demonstrated by our findings, LiCl reduces abnormal adipogenic activity and simultaneously increases the osteogenic differentiation of ONFH-BMMSCs by activating the β-catenin pathway.

Introduction

Recently, steroid-related osteonecrosis of the femoral head (ONFH) has been reported to occur in patients with collagen vascular diseases following high-dose steroid treatment (1). Several treatment strategies for ONFH have been implemented, including drug therapy and surgery. However, these methods have barely been effective in treating the disease. As steroid-related ONFH usually occurs in young and middle-aged patients and is associated with a poor prognosis (2), it is important to examine the pathophysiology of steroid-related ONFH and develop a preventive strategy.

Bone marrow-derived mesenchymal stem cells (BMMSCs) are multipotent cells that can differentiate into adipocytes or osteocytes (3). Changes in the functional characteristics of the differentiation pathway of BMMSCs may contribute to the pathogenesis of ONFH (4). Furthermore, interactions involving the differentiation pathway of BMMSCs that promote adipogenesis and decrease osteogenesis, are considered to be the major factors leading to steroid-related ONFH (5). Adipogenesis and osteogenesis share an inverse relationship in the bone marrow during the differentiation of BMMSCs (6). In ONFH, BMMSCs may differentiate preferentially into adipocytes rather than osteoblasts (7). Thus, the enhancement of osteogenesis coupled with a reduction in adipogenesis may provide a potential therapeutic strategy for the treatment of ONFH.

Wnt/β-catenin signaling functions as a molecular switch that determines the balance between osteogenesis and adipo-
genesis (8). Moreover, Wnt/β-catenin signaling is reportedly activated in osteoblast-committed MSCs, further indicating that it controls the balance between the osteogenesis and adipogenesis of MSCs (9). β-catenin is phosphorylated by a complex composed of adenomatous polyposis coli protein, glycogen synthase kinase 3β (GSK-3β) and axin. Following phosphorylation, β-catenin is subsequently decomposed (10,11). Lithium, which has been used in the treatment of bipolar disorder for years (12), may be used to inactivate GSK-3β, thus resulting in the accumulation of cytoplasmic β-catenin (13). Galli et al reported that lithium chloride (LiCl) enhanced osteogenesis in osteoblast-like MC3T3-E1 mouse cells (14). In addition, Itoi-gawa et al and Sen et al demonstrated that LiCl reduces the efficacy of adipogenic induction (15,16). However, LiCl has rarely been used in the treatment of ONFH, and the detailed mechanisms remain to be elucidated.

The benefits of LiCl are manifold; based on this fact, we thus hypothesized that LiCl may attenuate the abnormal osteogenic and adipogenic differentiation of BMMSCs obtained from rats with steroid-related ONFH through the activation of the β-catenin pathway.

Materials and methods

Animals. All the experimental procedures adhered to the recommendations of the Experimental Animal Center of Xi'an Jiaotong University, Xi'an, China, and were approved by the Ethics Committee of Xi'an Jiaotong University. A total of 45 male Sprague Dawley rats weighing 190-210 g were obtained from the Experimental Animal Center of Xi'an Jiaotong University. All the animals were housed under specific pathogen-free conditions in a clean, temperature and humidity-controlled environment with unlimited access to food and water and with a 12-h light/dark cycle.

Rat model of ONFH. A total of 30 rats underwent sequential drug administration to establish the ONFH model of ONFH as previously described (17). The remaining 15 rats were used as the normal controls. Briefly, the 30 rats were administered 2 mg/kg lipopolysaccharide (Sigma, St. Louis, MO, USA) intravenously for 2 days. One day later, 20 mg/kg of methylprednisolone (Pfizer, Inc., New York, NY, USA) was injected intramuscularly 3 times for 24 h. All the animals were sacrificed (via an intravenous injection of excess phenobarbital sodium) for the isolation of the BMMSCs 4 weeks after the final day of drug administration.

Preparation of rat BMMSCs. The BMMSCs were prepared as previously described (18). Briefly, BMMSCs were obtained from the femoral shafts of the rats (from the rats with ONFH and the normal rats) after the muscles and extraosteal tissues were trimmed. Bone marrow was flushed and centrifuged on a 1.073 g/ml Percoll density gradient (Pharmacia, St. Louis, MO, USA). The BMMSCs obtained from the rats with steroid-related ONFH are hereon referred to as ONFH-BMMSCs. The cells were washed with PBS (Wuhan Boster Biological Technology, Ltd., Wuhan, China), seeded into 25-cm² culture flasks, and cultivated in L-DMEM (Sigma) supplemented with 10% FBS (Sigma) and 20 mg penicillin-streptomycin/ml (Sigma) in a humidified 5% CO₂ atmosphere at 37°C. The medium was changed every 3 days. When the cells became subconfluent, the cells were released from the culture substratum using trypsin/EDTA (0.25% trypsin and 0.02% EDTA) (Sigma). The cell surface molecules, CD44 and CD34, were analyzed on 3 cultures by flow cytometry (FACSCalibur; Becton, Dickinson and Company, Franklin Lakes, NJ, USA).

ONFH-BMMSC viability assay. The ONFH-BMMSCs were plated into 96-well plates at a density of 2,000 cells/well. Following 4 h of incubation, some of the plates containing the ONFH-BMMSCs were treated with various concentrations of LiCl (1, 5, 10 and 20 mM; Sigma). The cells were then incubated at 37°C for 5 days. Following incubation, the cells were treated with methyl thiazolyl tetrazolium (MTT; 0.5 mg/ml) for 4 h at 37°C. Following solubilization with dimethyl sulfoxide, the absorbance was recorded at 570 nm using a microplate spectrophotometer (SpectraMax; Molecular Devices LLC, Sunnyvale, CA, USA).

Analysis of osteogenic differentiation. The BMMSCs were trypsinized and replated in a 6-well plate at a concentration of 2×10⁴ cells/well. The medium was replaced with osteogenic medium (low-glucose DMEM containing 5% FBS, 10 nM dexamethasone, 50 µM L-ascorbic acid-2-phosphate and 10 mM glycerophosphate; all from Sigma). The medium was added every other day, and the cells were maintained at 37°C in a humidified 5% CO₂ atmosphere. The differentiating cells were treated for 7, 14 and 21 days with osteogenic medium alone or medium containing 5 mM LiCl. The rat BMMSCs were divided into the following 3 groups: i) the normal group; ii) the ONFH-BMMSC group; and iii) the LiCl + ONFH-BMMSC group. The expression levels of osteocalcin (OCN) and Runx2 were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

After 21 days, mineralization was measured using Alizarin Red S (Sigma) staining. Briefly, the BMMSC cultures were fixed in 4% paraformaldehyde solution and stained with a 0.5% Alizarin Red (Sigma) solution. We added 1 ml of 10% cetylpyridinium chloride (Sigma) for quantitative analysis. The light absorbance of the extracted dye was measured using a spectrophotometer (UV-1800: Shimadzu, Kyoto, Japan) at 570 nm.

Analysis of adipogenic differentiation. The BMMSCs were seeded in 6-well plates at a concentration of 2×10⁵ cells/well and cultured in high-glucose DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, 10 µg/ml insulin, 1 µM dexamethasone and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; all from Sigma) at 37°C in a humidified 5% CO₂ atmosphere. The medium was changed every 2 days. The differentiating cells were treated for 3, 7 and 14 days with adipogenic medium alone or medium containing 5 mM LiCl. The expression levels of proliferator-activated receptor γ (PPARγ) and fatty acid binding protein 4 (Fabp4) were measured by RT-qPCR.

After 14 days, the BMMSCs were stained using Oil Red O. Briefly, the cells were fixed with 10% formalin. The cells were then washed with 60% isopropyl alcohol and stained with 2% Oil Red O reagent (Sigma). The staining was quantified by extracting the Oil Red O stain with 100% isopropyl alcohol,
after which the absorbance was measured using a spectrophotometer (UV-1800; Shimadzu) at 510 nm.

**RT-qPCR.** Briefly, total cellular RNA was extracted from the cultured cells using TRIzol reagent. Total RNA was then reverse transcribed into cDNA using an RT-PCR mixture (Takara Bio, Otsu, Japan). qPCR was performed in a reaction mixture containing SYBR-Green PCR Master Mix (Roche Diagnostics, Basel, Switzerland). β-actin was used as an internal control. The following primers were used in the present study: OCN sense, 5'-GAC AAG TCC CAC ACA GCA AC-3' and antisense, 5'-CCG GAG TCT ATT CAT CAC GCC CCA-3'; Runx2 sense, 5'-TCA CAA ATC TCT CCC AAG TGG-3' and antisense, 5'-GAA TGC GCC CTA AAT CAC TGA-3'; PPARγ sense, 5'-TCC TCC TGT TGA CCC AGA CTA-3' and antisense, 5'-AGC TGA TTC AGT TGG TGG-3'; Fabp4 sense, 5'-GGT ATT GTA AGT AAT CAC CCC-3' and antisense, 5'-TGG TCG ACT TTC CAT CCC ACT-3; and β-actin sense, 5'-AGT ACC CCA TTG AAC ACG GC-3' and antisense, 5'-TTT TCA CGG TTA GCC TTA GG-3'. The results were analyzed using SDS 2.0 software (Life Technologies, Grand Island, NY, USA).

**Western blot analysis.** To measure the protein expression of phosphorylated GSK-3β at Tyr-216 (p-Tyr216 GSK-3β) and β-catenin, we conducted western blot analysis. Total proteins were separated on 10% SDS-PAGE gels and then transferred onto polyvinylidene fluoride blotting membranes. After blocking non-specific binding with 5% BSA in Tween-Tris-buffered saline, the membranes were incubated with the following primary antibodies: anti-p-Tyr216 GSK-3β (ab75745; 1:500 dilution; Abcam, Cambridge, CA, USA), anti-β-catenin (ab32572; 1:1,000 dilution; Abcam) and anti-β-actin (BM0627; 1:200 dilution; Wuhan Boster Biological Technology, Ltd.) antibodies overnight. The membranes were then incubated for 2 h with secondary antibodies (ZDR-5306; 1:2,000 dilution; Zhongshan Golden Bridge Biotechnology, Co., Ltd., Beijing, China) labeled with horseradish peroxidase. The immunoreactive proteins on the blots were visualized using ECL™ Western blot detection reagents, and the signals were detected using Image Station 4000R (Kodak, Rochester, NY, USA).

**Inhibition of β-catenin pathway activation.** Quercetin (Que; Calbiochem, San Diego, CA, USA), an inhibitor of the β-catenin pathway (19,20), was used to further investigate the role of LiCl in the β-catenin pathway. The ONFH-BMMSCs were treated with 5 mM LiCl in the presence of Que (50 µM) and then underwent osteogenic and adipogenic differentiation. The LiCl + ONFH-BMMSC and ONFH-BMMSC groups were used as the controls in this experiment. The mRNA expression levels of Runx2 and Fabp4 were measured by quantitative RT-qPCR. The expression levels of OCN and Runx2 were separated on 10% SDS-PAGE gels and then transferred onto polyvinylidene fluoride blotting membranes. After blocking non-specific binding with 5% BSA in Tween-Tris-buffered saline, the membranes were incubated with the following primary antibodies: anti-OCN (ab13418) and anti-Fabp4 (ab92501) (Abcam). The cells were then stained with anti-OCN and anti-Fabp4 antibodies and visualized with a secondary antibody conjugated with tetraethyl rhodamine isothiocyanate (TRITC). The controls were also stained, but without the primary antibodies. Fluorescence images were acquired using a fluorescence microscope (Fluoview 500; Olympus, Tokyo, Japan). Data were analyzed using Image-Pro Plus 6.0 (Media Cybernetics, Inc., Rockville, MD, USA).

**Statistical analysis.** The data are expressed as the means ± standard deviation (SD). Data analysis was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). One-way analysis of variance followed by an LSD test was used for comparisons among the experimental groups. P-values <0.05 were considered to indicate statistically significant differences.

**Results**

**Characterization of rat BMMSCs.** The BMMSCs were successfully and rapidly expanded into colonies of confluent spindle-shaped cells. The results of flow cytometry for CD34 and CD44 revealed that the cells were negative for CD34 (0.57%) and positive for CD44 (99.43%) (data not shown). The cultured cells were thus considered BMMSCs.

**Effect of LiCl on the viability of ONFH-BMMSCs.** We tested a range of LiCl concentrations to determine the optimal concentration to treat the ONFH-BMMSCs with. The OD value provided by the MTT assay in the low-dose LiCl-treated groups (1 and 5 mM) was significantly higher than that of the control group (P<0.001; Fig. 1). Treatment with LiCl at up to 5 mM increased cell viability in a dose-dependent manner. On the contrary, in the high-dose LiCl-treated groups (10 and 20 mM), LiCl exerted an inhibitory effect on cell viability (P<0.001; Fig. 1).

**LiCl enhances the osteogenesis of ONFH-BMMSCs.** The results revealed that the 5 mM LiCl treatment group and the normal group exhibited a significant increase in the mRNA expression of OCN and Runx2 in a time-dependent manner compared with the ONFH-BMMSC group (P<0.001; Fig. 2). Furthermore, we
YU et al: LiCl ATTENUATES THE ABNORMAL OSTEOGENIC/ADIPOGENIC DIFFERENTIATION OF ONFH-BMMSCs

found that the OCN and Runx2 mRNA levels did not significantly differ between the LiCl + ONFH-BMMSC group and the normal BMMSC group (P>0.05; Fig. 2).

The results revealed that the normal and the LiCl + ONFH-BMMSC groups presented with a greater number of mineralized nodules than the ONFH-BMMSC group (Fig. 3A-C). Furthermore, the light absorbance analysis revealed that the normal and LiCl + ONFH-BMMSC groups had significantly higher OD values than the ONFH-BMMSC group (P<0.001); by contrast, the OD values did not differ between the normal and the LiCl + ONFH-BMMSC groups (P>0.05; Fig. 3D).

LiCl reduces the adipogenesis of ONFH-BMMSCs. The LiCl treatment group and normal group exhibited a significant decrease in the mRNA expression of PPARγ and Fabp4 compared with the ONFH-BMMSC group (P<0.001, Fig. 4).
Furthermore, we found that the LiCl treatment group showed no statistically significant differences in the PPARγ and Fabp4 mRNA expression levels compared with the normal BMMSC group (P>0.05; Fig. 4).

The results obtained from Oil Red O staining revealed that the normal and LiCl + ONFH-BMMSC groups presented with fewer lipid droplets than the ONFH-BMMSC group (Fig. 5A-C). Moreover, the light absorbance analysis revealed that the normal and LiCl + ONFH-BMMSC groups had significantly lower OD values than the ONFH-BMMSC group (P<0.001), while the OD values between the normal and the LiCl + ONFH-BMMSC groups did not differ (P>0.05; Fig. 5D).

**LiCl activates the β-catenin pathway.** As shown in Fig. 6, treatment with LiCl markedly increased the expression of β-catenin and decreased the p-Tyr216 GSK-3β protein levels compared...
YU et al: LiCl ATTENUATES THE ABNORMAL OSTEOGENIC/ADIPOGENIC DIFFERENTIATION OF ONFH-BMMSCs

with the ONFH-BMMSC group (P<0.001). The normal group exhibited a higher expression of β-catenin and a lower expression of p-Tyr216 GSK-3β compared with the ONFH-BMMSC group (P<0.001).

\textbf{Inhibition of β-catenin pathway diminishes the effects of LiCl.}

The LiCl + Que + ONFH-BMMSC and ONFH-BMMSC groups exhibited no statistically significant difference in PPARγ and Runx2 mRNA levels compared with the ONFH-BMMSC group (P>0.05; Fig. 7).

\textbf{Immunofluorescence staining revealed that the LiCl + Que + ONFH-BMMSC and ONFH-BMMSC groups exhibited a significant increase in Fabp4 expression compared with the LiCl + ONFH group (P<0.001; Fig. 8A). By contrast, the LiCl + Que + ONFH-BMMSC and ONFH-BMMSC groups exhibited a significantly lower expression of OCN (P<0.001; Fig. 8B). Moreover, we also found that the LiCl + Que + ONFH-BMMSC group exhibited no statistically significant difference in Fabp4 and OCN expression compared with the ONFH-BMMSC group (P>0.05; Fig. 8).}
Discussion

ONFH is a common degenerative disease that mostly occurs in young and middle age. The disease critically affects the quality of life of patients and is associated with a high morbidity. Hernigou et al demonstrated that the decreased activity of BMMSCs may contribute to the pathogenesis of ONFH (4). In a previous study, in patients who developed osteonecrosis following treatment with corticosteroids, abnormal adipogenesis was discovered in the bone marrow, with a decreased number of osteogenic cells (21). These findings indicate that steroids may disrupt the osteogenic/adipogenic activity of stem cells in ONFH.

To explore the potential impairment in the osteogenic/adipogenic activity of BMMSCs in ONFH, we established a rat model of steroid-related ONFH previously reported by Chen et al (17). According to their study, the necrosis generated in this model is similar to that observed in steroid-treated patients. In the present study, Alizarin Red S staining determined the osteogenic function of BMMSCs in the model group, which was impaired compared with the normal BMMSCs. By contrast, Oil Red O staining indicated that the adipogenic function of BMMSCs isolated from rats with steroid-related ONFH was enhanced compared with normal BMMSCs. These results indicated that the differentiation of ONFH-BMMSCs was impaired, which may be the cause of steroid-related ONFH.

Lithium has been used in the treatment of bipolar disorder for decades, and its safety has been well confirmed (22). Studies have reported that lithium inhibits the adipogenic effect (15,16). Mai et al also confirmed the anti-adipogenic effects of LiCl (23). LiCl has also been reported to stimulate osteoblast differentiation (14). However, it remains unknown as to whether lithium can reverse the abnormal osteogenic/adipogenic activity of BMMSCs from rats with steroid-related ONFH. In the present study, we examined the possibility of using LiCl to reverse the abnormal differentiation of ONFH-BMMSCs. The effects of lithium have been reported to be highly dependent on its concentration (24,25); thus, we tested a series of LiCl concentrations to find the optimal concentration. We found that 5 mM LiCl exerted the greatest stimulatory...
effect on the viability of ONFH-BMMSCs. Thus, we selected 5 mM LiCl as the optimal concentration.

Runx2 is essential for osteoblast differentiation and skeletal morphogenesis. Moreover, OCN, also known as bone gamma-carboxyglutamic acid-containing protein (BGLAP), is a non-collagenous protein found in bone (26). It has been implicated in bone mineralization and calcium ion homeostasis (27).

In the present study, we found the decreased expression of Runx2 and OCN in the ONFH-BMMSCs, suggesting that steroid-related ONFH reduces the osteogenic activity of BMMSCs. Following treatment with LiCl, the expression of Runx2 and OCN significantly increased, and this was consistent with the results of Alizarin Red S staining. These results indicate that LiCl can reverse the abnormal osteogenic differentiation of ONFH-BMMSCs.

By contrast, PPARγ, as a member of the nuclear receptor gene superfamily of ligand-activated transcription factors, functions as a stimulator of bone marrow adipogenesis and an inhibitor of osteogenesis. Fabp4 is a carrier protein for fatty acids that is considered to be a terminal differentiation marker for adipocytes (28). In the present study, we found the increased expression of PPARγ and Fabp4 in the BMMSCs from rats with steroid-related ONFH, indicating that steroid-related ONFH may cause BMMSCs to change into an adipogenic phenotype. Following treatment with LiCl, the expression of PPARγ and Fabp4 significantly decreased. These results were consistent with those of Oil Red O staining, suggesting that lithium attenuates the impairment of excessive adipogenic differentiation of ONFH-BMMSCs.

Lithium, as used in the present study, is known to be a GSK-3β inhibitor that can raise the β-catenin concentration (14). The Wnt/β-catenin pathway has been reported to inhibit adipocyte differentiation (29), as well as enhance osteoblast differentiation (30). As a key component of this pathway, the activation of β-catenin leads to the direct suppression of PPARγ and the prevention of 3T3-L1 cell adipogenic differentiation (31,32). By contrast, the disruption of the β-catenin pathway increases adipogenesis (33) and reduces bone formation (29). In addition, GSK-3β activity is regulated by phosphorylation and Tyr216 phosphorylation increases its activity (34) and Garza et al (35) reported that steroids inhibit GSK-3β/β-catenin signaling by activating GSK-3β. This activation inhibited the activity of β-catenin (35) and was consistent with our present findings that the ONFH-BMMSCs had decreased levels of β-catenin and increased levels of p-Tyr216 GSK-3β (active form of GSK-3β) compared with the normal BMMSCs. The results of western blot analysis in the present study revealed that LiCl, as a GSK-3β inhibitor, activated β-catenin by reducing p-Tyr216 GSK-3β. However, whether lithium attenuated the abnormal osteogenic/adipogenic differentiation of ONFH-BMMSCs through the β-catenin pathway remains uncertain. To further elucidate the possible mechanisms of action of lithium in ONFH-BMMSCs, we used Que, an inhibitor of the β-catenin pathway. We found that the treatment effects of LiCl (the attenuation of the abnormal osteogenic and adipogenic differentiation) on ONFH-BMMSCs were abolished by treatment with Que. In this respect, we speculated that lithium may act as a switch to reduce both the abnormal adipogenic activity and increase the osteogenic differentiation of ONFH-BMMSCs by activating the β-catenin pathway.

In conclusion, our data indicate that the normal osteogenic/adipogenic activity of BMMSCs is impaired during steroid-related ONFH. The present study also provides evidence to suggest that LiCl attenuates the abnormal osteogenic/adipogenic differentiation of BMMSCs obtained from rats with steroid-related ONFH by activating the β-catenin signaling pathway. These findings highlight the treatment effects of LiCl on steroid-related ONFH and provide an effective therapeutic strategy.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant nos. 81101363, 81371944 and 81572145) and the Fundamental Research Funds for the Central Universities.

References

1. Sun Z, Yang S, Ye S, Zhang Y, Xu W, Zhang B, Liu X, Mo F and Hua W: Aberrant Cpg islands' hypermethylation of ABCB1 in mesenchymal stem cells of patients with steroid-associated osteonecrosis. J Rheumatol 40: 1913-1920, 2013.
2. Lieberman JR, Berry DJ, Mont MA, Aaron RK, Callaghan JJ, Rajadhyaksha AD and Uebaianik JR: Osteonecrosis of the hip: management in the 21st century. Instr Course Lect 52: 337-355, 2003.
3. Webster RA, Blaber SP, Herbert BR, Wilkins MR and Vesey G: The role of mesenchymal stem cells in veterinary therapeutics - a review. N Z Vet J 60: 265-272, 2012.
4. Hernigou P and Beaudeau F: Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. J Bone Joint Surg Am 79: 1047-1053, 1997.
5. Seamon J, Keller T, Saleh J and Cui Q: The pathogenesis of nontraumatic osteonecrosis. Arthritis (Egypt) 2012: 601763, 2012.
6. Abdallah BM and Kassem M: New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone 50: 540-545, 2012.
7. Sheng H, Sheng CJ, Cheng XY, Zhang G, Lee KM, Leung KS, Qu S and Qin L: Pathomorphological changes of bone marrow adipocytes in process of steroid-associated osteonecrosis. Int J Clin Exp Pathol 6: 1046-1050, 2013.
8. Taipaleenmäki H, Abdallah BM, AlDahmasah A, Säämänen AM and Kassem M: Wnt signalling mediates the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations. Exp Cell Res 317: 745-756, 2011.
9. Franceschi RT and Xiao G: Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88: 446-454, 2003.
10. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-847, 2002.
11. Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell 149: 1192-1205, 2012.
12. Young W: Review of lithium effects on brain and blood. Cell Transplant 18: 951-975, 2009.
13. Wexler EM, Geschwind DH and Palmer TD: Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 13: 285-292, 2008.
14. Galli C, Piemontese M, Lumiatti S, Manfredi E, Macaluso GM and Passeri G: GSK3β-inhibitor lithium chloride enhances activation of Wnt canonical signaling and osteoblast differentiation on hydrophilic titanium surfaces. Clin Oral Implants Res 24: 921-927, 2013.
15. Itiojawa Y, Kishimoto KN, Sano H, Kaneko K and Itoi E: GSK βcatenin signaling and disease. Cell Transplant 18: 951-975, 2009.
16. Chen S, Li J, Peng H, Zhou J and Fang H: Administration of erythropoietin exerts protective effects against glucocorticoid-induced osteonecrosis of the femoral head in rats. Int J Mol Med 33: 840-848, 2014.
18. Panepucci RA, Siufi JLC, Silva WA Jr, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT and Zago MA: Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 22: 1263-1278, 2004.

19. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Kitaichi Y, Inoue T and Koyama T: Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrus-derived neural precursor cells through GSK-3beta and beta-catenin/Tcf pathway. Neuropsychopharmacology 34: 805-815, 2009.

20. Park CH, Chang JY, Hahn ER, Park S, Kim HK and Yang CH: Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 328: 227-234, 2005.

21. Cui Q, Wang GJ and Balian G: Pluripotential marrow cells produce adipocytes when transplanted into steroid-treated mice. Connect Tissue Res 41: 45-56, 2000.

22. Jope RS: Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441-443, 2003.

23. Liu J and Farmer SR: Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279: 45020-45027, 2004.

24. Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG and Prockop DJ: Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem 280: 2309-2323, 2005.

25. Makita N, Suzuki M, Asami S, Takahata R, Kohzaki D, Kobayashi S, Hakamazuka T and Hozumi N: Two of four alternatively spliced isoforms of RUNX2 control osteocalcin gene expression in human osteoblast cells. Gene 413: 8-17, 2008.

26. Lin GT, Tseng HF, Chang CK, Chuang LY, Liu CS, Yang CH, Tu CJ, Wang EC, Tan HF, Chang CC, et al: SNP combinations in chromosome-wide genes are associated with bone mineral density in Taiwanese women. Chin J Physiol 51: 32-41, 2008.